BMRA
Biomerica, Inc.
Price Chart
Latest Quote
$1.72
+0.04 (+2.38%)
Current Price
| Previous Close | $1.68 |
| Open | $1.67 |
| Day High | $1.79 |
| Day Low | $1.67 |
| Volume | 31 |
Stock Information
| Shares Outstanding | 4.60M |
| Total Debt | $2.33M |
| Cash Equivalents | $2.73M |
| Revenue | $4.34M |
| Net Income | $-5.01M |
| Sector | Healthcare |
| Industry | Medical Devices |
| Market Cap | $7.86M |
| EPS (TTM) | $-1.64 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $7.50M |
| Sales | $4.34M |
| Income | $-5.01M |
| Book/sh | $0.79 |
| Cash/sh | $0.59 |
| Employees | 50 |
Financial Ratios
| Quick Ratio | 1.28 |
| Current Ratio | 1.91 |
| Debt/Eq | 63.76 |
Returns & Margins
| ROA | -45.47% |
| ROE | -113.80% |
| Gross Margin | 0.95% |
| Operating Margin | -97.00% |
| Profit Margin | -115.47% |
Ownership
| Insider Ownership | 21.90% |
| Institutional Ownership | 2.72% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 4.38 |
| P/S | 1.81 |
| P/B | 2.16 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $1.88 |
| SMA50 | $2.05 |
| SMA200 | $2.06 |
| RSI | 28.26 |
| ATR | 0.0971 |
| Shares Float | 4.25M |
| Short Float | 0.65% |
| Short Ratio | 0.75 |
| Volatility | 0.38 |
| Rel Volume | 0.59 |
Performance History
| Week | -0.58% |
| Month | -28.45% |
| Quarter | +7.55% |
| 6 Months | -21.56% |
| YTD | -32.41% |
| Year | -42.23% |
| 3 Years | -73.28% |
| 5 Years | -96.11% |
| 10 Years | -91.45% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $1.71 | 7,063 |
| 2026-10-26 | $1.72 | 10,400 |
| 2026-10-23 | $1.68 | 12,000 |
| 2026-10-22 | $1.68 | 2,000 |
| 2026-10-21 | $1.71 | 7,500 |
| 2026-10-20 | $1.72 | 6,000 |
| 2026-10-19 | $1.76 | 13,300 |
| 2026-10-16 | $1.85 | 13,200 |
| 2026-10-15 | $1.88 | 13,800 |
| 2026-10-14 | $1.80 | 18,600 |
| 2026-10-13 | $1.85 | 13,300 |
| 2026-10-12 | $1.84 | 4,900 |
| 2026-10-09 | $1.84 | 10,300 |
| 2026-10-08 | $1.89 | 6,600 |
| 2026-10-07 | $1.91 | 34,700 |
| 2026-10-06 | $2.14 | 11,100 |
| 2026-10-05 | $2.05 | 33,900 |
| 2026-10-02 | $2.14 | 8,400 |
| 2026-10-01 | $2.24 | 2,200 |
| 2026-09-30 | $2.26 | 11,400 |
| 2026-09-29 | $2.30 | 2,500 |
| 2026-09-28 | $2.39 | 7,100 |
About Biomerica, Inc.
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases in North America, Asia, Europe, the Middle East, and South America. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions, as well as detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens, and other substances that may exist in the human body at extremely low concentrations through clinical laboratories and in point-of-care settings, including physicians' offices and over-the-counter channels. It also provides contract development and manufacturing services to third parties. In addition, the company commercializes inFoods IBS product through physician-directed and laboratory-based channels, such as third-party reimbursement pathways. Further, it is involved in the development and optimization of immunoassays, enzyme-linked immunosorbent assays, rapid diagnostic tests, and related diagnostic technologies; and research, development, commercialization of diagnostic-guided therapy (DGT) products to treat gastrointestinal diseases, such as irritable bowel syndrome (IBS), and other inflammatory diseases. Additionally, the company offers EZ detect colon disease home test; Aware Breast Self-Exam product; and hp+detect, a diagnostic test designed to detect Helicobacter pylori (H. pylori) bacteria in the gastrointestinal tract. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on BMRA.
Period:
Loading...
Income Statement (Annual)
| Metric | 2026-05-31 | 2025-05-31 | 2024-05-31 | 2023-05-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $4,091,000 | $4,813,000 | $4,804,000 | $4,893,000 |
| Cost Of Revenue | $4,091,000 | $4,813,000 | $4,804,000 | $4,893,000 |
| Total Revenue | $4,453,000 | $5,311,000 | $5,415,000 | $5,339,000 |
| Operating Revenue | $4,453,000 | $5,311,000 | $5,415,000 | $5,339,000 |
| Expenses | ||||
| Total Expenses | $9,773,000 | $10,448,000 | $11,782,000 | $12,562,000 |
| Other Income Expense | $335,000 | - | - | $1,000 |
| Net Non Operating Interest Income Expense | $1,233,000 | $165,000 | $431,000 | $133,000 |
| Operating Expense | $5,682,000 | $5,635,000 | $6,978,000 | $7,669,000 |
| Other Non Operating Income Expenses | - | - | - | $1,000 |
| Interest Expense | - | - | - | - |
| Interest Expense Non Operating | - | - | - | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-3,775,000 | $-4,973,000 | $-5,978,000 | $-7,140,000 |
| Net Interest Income | $1,233,000 | $165,000 | $431,000 | $133,000 |
| Interest Income | $1,233,000 | $165,000 | $431,000 | $133,000 |
| Normalized Income | $-3,976,000 | $-4,973,000 | $-5,978,000 | $-7,140,000 |
| Net Income From Continuing And Discontinued Operation | $-3,775,000 | $-4,973,000 | $-5,978,000 | $-7,140,000 |
| Total Operating Income As Reported | $-5,320,000 | $-5,137,000 | $-6,367,000 | $-7,223,000 |
| Net Income Common Stockholders | $-3,775,000 | $-4,973,000 | $-5,978,000 | $-7,140,000 |
| Net Income | $-3,775,000 | $-4,973,000 | $-5,978,000 | $-7,140,000 |
| Net Income Including Noncontrolling Interests | $-3,775,000 | $-4,973,000 | $-5,978,000 | $-7,140,000 |
| Net Income Continuous Operations | $-3,775,000 | $-4,973,000 | $-5,978,000 | $-7,140,000 |
| Pretax Income | $-3,752,000 | $-4,972,000 | $-5,936,000 | $-7,089,000 |
| Interest Income Non Operating | $1,233,000 | $165,000 | $431,000 | $133,000 |
| Operating Income | $-5,320,000 | $-5,137,000 | $-6,367,000 | $-7,223,000 |
| Gross Profit | $362,000 | $498,000 | $611,000 | $446,000 |
| Per Share | ||||
| Diluted EPS | - | $-2.16 | $-2.84 | $-4.00 |
| Basic EPS | - | $-2.16 | $-2.84 | $-4.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $134,000 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-5,234,000 | $-4,737,000 | $-5,993,000 | $-6,872,000 |
| Total Unusual Items | $335,000 | - | - | - |
| Total Unusual Items Excluding Goodwill | $335,000 | - | - | - |
| Reconciled Depreciation | $421,000 | $400,000 | $374,000 | $351,000 |
| EBITDA (Bullshit earnings) | $-4,899,000 | $-4,737,000 | $-5,993,000 | $-6,872,000 |
| EBIT | $-5,320,000 | $-5,137,000 | $-6,367,000 | $-7,223,000 |
| Diluted NI Availto Com Stockholders | $-3,775,000 | $-4,973,000 | $-5,978,000 | $-7,140,000 |
| Tax Provision | $23,000 | $1,000 | $42,000 | $51,000 |
| Gain On Sale Of Security | $335,000 | - | - | - |
| Research And Development | $788,000 | $1,023,000 | $1,491,000 | $1,584,000 |
| Selling General And Administration | $4,894,000 | $4,612,000 | $5,487,000 | $6,085,000 |
| Diluted Average Shares | - | $2,297,057 | $2,103,154 | $1,769,283 |
| Basic Average Shares | - | $2,297,057 | $2,103,154 | $1,769,283 |
Fetched: 2026-10-11
Balance Sheet (Annual)
| Metric | 2026-05-31 | 2025-05-31 | 2024-05-31 | 2023-05-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $2,421,000 | $3,877,000 | $6,379,000 | $11,559,000 |
| Total Assets | $6,759,000 | $5,945,000 | $9,254,000 | $14,454,000 |
| Total Non Current Assets | $2,743,000 | $1,070,000 | $1,523,000 | $1,657,000 |
| Other Non Current Assets | $83,000 | $113,000 | $203,000 | $79,000 |
| Investmentin Financial Assets | $500,000 | $165,000 | $165,000 | $165,000 |
| Goodwill And Other Intangible Assets | $209,000 | $228,000 | $212,000 | $165,000 |
| Other Intangible Assets | $209,000 | $228,000 | $212,000 | $165,000 |
| Current Assets | $4,016,000 | $4,875,000 | $7,731,000 | $12,797,000 |
| Other Current Assets | $216,000 | $255,000 | $238,000 | $300,000 |
| Inventory | $1,707,000 | $1,490,000 | $2,376,000 | $2,056,000 |
| Receivables | $785,000 | $731,000 | $947,000 | $722,000 |
| Accounts Receivable | $785,000 | $731,000 | $947,000 | $722,000 |
| Allowance For Doubtful Accounts Receivable | $-38,000 | $-26,000 | $-19,000 | $-29,000 |
| Gross Accounts Receivable | $823,000 | $757,000 | $966,000 | $751,000 |
| Cash Cash Equivalents And Short Term Investments | $1,308,000 | $2,399,000 | $4,170,000 | $9,719,000 |
| Cash And Cash Equivalents | $1,308,000 | $2,399,000 | $4,170,000 | $9,719,000 |
| Prepaid Assets | - | - | $238,000 | $300,000 |
| Debt | ||||
| Total Debt | $2,383,000 | $458,000 | $785,000 | $1,082,000 |
| Long Term Debt And Capital Lease Obligation | $1,648,000 | $100,000 | $459,000 | $785,000 |
| Current Debt And Capital Lease Obligation | $735,000 | $358,000 | $326,000 | $297,000 |
| Current Debt | $500,000 | - | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $4,129,000 | $1,840,000 | $2,663,000 | $2,730,000 |
| Total Non Current Liabilities Net Minority Interest | $1,648,000 | $100,000 | $459,000 | $785,000 |
| Current Liabilities | $2,481,000 | $1,740,000 | $2,204,000 | $1,945,000 |
| Current Deferred Liabilities | $83,000 | $55,000 | $85,000 | $60,000 |
| Current Notes Payable | $500,000 | $0 | - | - |
| Payables And Accrued Expenses | $1,171,000 | $672,000 | $1,138,000 | $892,000 |
| Payables | $377,000 | $295,000 | $560,000 | $344,000 |
| Accounts Payable | $377,000 | $295,000 | $560,000 | $344,000 |
| Other Current Liabilities | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $2,630,000 | $4,105,000 | $6,591,000 | $11,724,000 |
| Total Equity Gross Minority Interest | $2,630,000 | $4,105,000 | $6,591,000 | $11,724,000 |
| Stockholders Equity | $2,630,000 | $4,105,000 | $6,591,000 | $11,724,000 |
| Gains Losses Not Affecting Retained Earnings | $-108,000 | $-105,000 | $-102,000 | $-110,000 |
| Other Equity Adjustments | $-108,000 | $-105,000 | $-102,000 | $-110,000 |
| Retained Earnings | $-56,943,000 | $-53,168,000 | $-48,195,000 | $-42,217,000 |
| Other | ||||
| Ordinary Shares Number | $3,090,269 | $2,546,216 | $2,102,705 | $2,102,705 |
| Share Issued | $3,090,269 | $2,546,216 | $2,102,705 | $2,102,705 |
| Tangible Book Value | $2,421,000 | $3,877,000 | $6,379,000 | $11,559,000 |
| Invested Capital | $3,130,000 | $4,105,000 | $6,591,000 | $11,724,000 |
| Working Capital | $1,535,000 | $3,135,000 | $5,527,000 | $10,852,000 |
| Capital Lease Obligations | $1,883,000 | $458,000 | $785,000 | $1,082,000 |
| Total Capitalization | $2,630,000 | $4,105,000 | $6,591,000 | $11,724,000 |
| Additional Paid In Capital | $59,426,000 | $57,175,000 | $54,720,000 | $52,705,000 |
| Capital Stock | $255,000 | $203,000 | $168,000 | $1,346,000 |
| Common Stock | $255,000 | $203,000 | $168,000 | $1,346,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $1,648,000 | $100,000 | $459,000 | $785,000 |
| Current Deferred Revenue | $83,000 | $55,000 | $85,000 | $60,000 |
| Current Capital Lease Obligation | $235,000 | $358,000 | $326,000 | $297,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $492,000 | $655,000 | $655,000 | $696,000 |
| Current Accrued Expenses | $794,000 | $377,000 | $578,000 | $548,000 |
| Investments And Advances | $500,000 | $165,000 | $165,000 | $165,000 |
| Net PPE | $1,951,000 | $564,000 | $943,000 | $1,248,000 |
| Accumulated Depreciation | $-1,503,000 | $-2,683,000 | $-2,304,000 | $-1,948,000 |
| Gross PPE | $3,454,000 | $3,247,000 | $3,247,000 | $3,196,000 |
| Other Properties | $3,243,000 | $3,036,000 | $3,036,000 | $2,985,000 |
| Machinery Furniture Equipment | $211,000 | $211,000 | $211,000 | $211,000 |
| Inventories Adjustments Allowances | $-394,000 | $-471,000 | $-467,000 | $-672,000 |
| Finished Goods | $179,000 | $147,000 | $179,000 | $182,000 |
| Work In Process | $868,000 | $743,000 | $1,145,000 | $869,000 |
| Raw Materials | $1,054,000 | $1,071,000 | $1,519,000 | $1,677,000 |
Fetched: 2026-10-11
Cash Flow Statement (Annual)
| Metric | 2026-05-31 | 2025-05-31 | 2024-05-31 | 2023-05-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-3,422,000 | $-3,879,000 | $-5,476,000 | $-5,552,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-3,421,000 | $-3,842,000 | $-5,361,000 | $-5,474,000 |
| Cash Flow From Continuing Operating Activities | $-3,421,000 | $-3,842,000 | $-5,361,000 | $-5,474,000 |
| Operating Gains Losses | - | - | - | - |
| Investing Activities | ||||
| Capital Expenditure | $-1,000 | $-37,000 | $-115,000 | $-78,000 |
| Investing Cash Flow | $-1,000 | $-37,000 | $-115,000 | $-78,000 |
| Cash Flow From Continuing Investing Activities | $-1,000 | $-37,000 | $-115,000 | $-78,000 |
| Capital Expenditure Reported | $-1,000 | $-37,000 | $-64,000 | $-14,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $2,374,000 | $2,143,000 | $0 | $10,014,000 |
| Financing Cash Flow | $2,334,000 | $2,111,000 | $-81,000 | $9,390,000 |
| Cash Flow From Continuing Financing Activities | $2,334,000 | $2,111,000 | $-81,000 | $9,390,000 |
| Net Other Financing Charges | $-40,000 | $-47,000 | $-81,000 | $-705,000 |
| Net Common Stock Issuance | $2,374,000 | $2,143,000 | $0 | $10,014,000 |
| Common Stock Issuance | $2,374,000 | $2,143,000 | $0 | $10,014,000 |
| Repurchase Of Capital Stock | - | - | $0 | $-705,000 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Income Tax Paid Supplemental Data | $22,000 | $10,000 | $41,000 | $51,000 |
| End Cash Position | $1,308,000 | $2,399,000 | $4,170,000 | $9,719,000 |
| Beginning Cash Position | $2,399,000 | $4,170,000 | $9,719,000 | $5,917,000 |
| Effect Of Exchange Rate Changes | $-3,000 | $-3,000 | $8,000 | $-36,000 |
| Changes In Cash | $-1,088,000 | $-1,768,000 | $-5,557,000 | $3,838,000 |
| Proceeds From Stock Option Exercised | $0 | $15,000 | $0 | $81,000 |
| Change In Working Capital | $-143,000 | $259,000 | $-389,000 | $304,000 |
| Change In Other Working Capital | $28,000 | $-30,000 | $15,000 | $351,000 |
| Change In Other Current Liabilities | $-363,000 | $-327,000 | $-297,000 | $-297,000 |
| Change In Other Current Assets | $23,000 | $9,000 | $-44,000 | $18,000 |
| Change In Payables And Accrued Expense | $336,000 | $-467,000 | $205,000 | $-31,000 |
| Change In Accrued Expense | $-163,000 | $0 | $-41,000 | $49,000 |
| Change In Payable | $499,000 | $-467,000 | $246,000 | $-80,000 |
| Change In Account Payable | $499,000 | $-467,000 | $246,000 | $-80,000 |
| Change In Prepaid Assets | $39,000 | $-17,000 | $62,000 | $20,000 |
| Change In Inventory | $-140,000 | $882,000 | $-115,000 | $534,000 |
| Change In Receivables | $-66,000 | $209,000 | $-215,000 | $-291,000 |
| Changes In Account Receivables | $-66,000 | $209,000 | $-215,000 | $-291,000 |
| Other Non Cash Items | $-335,000 | - | - | - |
| Stock Based Compensation | $476,000 | $460,000 | $837,000 | $1,185,000 |
| Provisionand Write Offof Assets | $-65,000 | $12,000 | $-205,000 | $-174,000 |
| Depreciation Amortization Depletion | $421,000 | $400,000 | $374,000 | $351,000 |
| Depreciation And Amortization | $421,000 | $400,000 | $374,000 | $351,000 |
| Depreciation | $344,000 | $313,000 | $374,000 | $351,000 |
| Net Income From Continuing Operations | $-3,775,000 | $-4,973,000 | $-5,978,000 | $-7,140,000 |
| Net PPE Purchase And Sale | - | $0 | $-51,000 | $-64,000 |
| Purchase Of PPE | - | $0 | $-51,000 | $-64,000 |
| Common Stock Payments | - | - | $0 | $-705,000 |
| Net Intangibles Purchase And Sale | - | - | - | $-14,000 |
| Purchase Of Intangibles | - | - | - | $-14,000 |
| Gain Loss On Sale Of PPE | - | - | - | $0 |
| Interest Paid Supplemental Data | - | - | - | - |
Fetched: 2026-10-11